Pfizer

4Q Revenues: $13.6 billion (-3%)

4Q Earnings: $775 million (loss of $172 million 4Q15)

FY Revenues: $52.8 billion (+8%)

FY Earnings: $7.2 billion (+4%)

Comments: Innovative Health sales were $29.2 billion for the year, up 9%. Essential health sales were $23.6 billion, up 7%. Lyrica sales were $4.2 billion, up 14% for the year. Viagra sales were $1.2 billion, down 9%. Chantix sales were $842 million, up 26%. Loss of exclusivity for Prevnar 13 Adult impacted sales in the U.S., down 8% to $5.7 billion. Ibrance sales were $2.1 billion, up from $723 million FY15. Sutent sales were $1.1 billion, down 2%. Enbrel sales were down 13% to $2.9 billion. Xeljanz sales were up 77% to $927 million. Lipitor sales were $1.8 billion, down 6%. Premarin sales were flat at $1.0 billion. R&D expenses were $7.9 billion, up 2%. Financial results reflect legacy Hospira global operations, as well as the June 2016 acquisition Anacor Pharmaceuticals, which reflects three and six months of legacy operations.